Bioactive CD4 ligands as pre- and/or postbinding inhibitors of HIV-1.
Briant
L
L
Laboratoire Infections Rétrovirales et Signalisation Cellulaire, CNRS EP 2104, Montpellier, France.
Devaux
C
C
D000163:Acquired Immunodeficiency Syndrome / Q000628:therapy; D019380:Anti-HIV Agents / Q000494:pharmacology*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D015704:CD4 Antigens / Q000276:immunology / Q000378:metabolism*; D022801:Complementarity Determining Regions; D015693:Gene Products, nef / Q000378:metabolism; D015699:HIV Envelope Protein gp120 / Q000378:metabolism; D016325:HIV Long Terminal Repeat; D015497:HIV-1 / Q000187:drug effects*; D000949:Histocompatibility Antigens Class II / Q000378:metabolism; D006801:Humans; D019410:Interleukin-16 / Q000378:metabolism; D019860:Lymphocyte Specific Protein Tyrosine Kinase p56(lck) / Q000378:metabolism; D013329:Structure-Activity Relationship; D054311:nef Gene Products, Human Immunodeficiency Virus
D019380:Anti-HIV Agents; D000911:Antibodies, Monoclonal; D015704:CD4 Antigens; D022801:Complementarity Determining Regions; D015693:Gene Products, nef; D015699:HIV Envelope Protein gp120; D000949:Histocompatibility Antigens Class II; D019410:Interleukin-16; D054311:nef Gene Products, Human Immunodeficiency Virus; D019860:Lymphocyte Specific Protein Tyrosine Kinase p56(lck)